EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation

Tim J Palmer iD, Kimberley Kavanagh, Kate Cuschieri iD, Ross Cameron, Catriona Graham, Allan Wilson, Kirsty Roy

JNCI: Journal of the National Cancer Institute · 07.06.2024 · 116 (6) · 857-865

DOI: 10.1093/jnci/djad263 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 22.01.2024. Verfasst von Tim J Palmer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Public Health Scotland, Glasgow, UK. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Vaccines, Papillomavirus Infections. Die Arbeit wurde bisher 158-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Scottish Government, Public Health Scotland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High-risk human papillomavirus causes cervical cancer. Vaccines have been developed that significantly reduce the incidence of preinvasive and invasive disease. This population-based observational study used linked screening, immunization, and cancer registry data from Scotland to assess the influence of age, number of doses, and deprivation on the incidence of invasive disease following administration of the bivalent vaccine.

Methods

Data for women born between January 1, 1988, and June 5, 1996, were extracted from the Scottish cervical cancer screening system in July 2020 and linked to cancer registry, immunization, and deprivation data. Incidence of invasive cervical cancer per 100 000 person-years and vaccine effectiveness were correlated with vaccination status, age at vaccination, and deprivation; Kaplan Meier curves were calculated.

Results

No cases of invasive cancer were recorded in women immunized at 12 or 13 years of age irrespective of the number of doses. Women vaccinated at 14 to 22 years of age and given 3 doses of the bivalent vaccine showed a significant reduction in incidence compared with all unvaccinated women (3.2/100 000 [95% confidence interval (CI) = 2.1 to 4.6] vs 8.4 [95% CI = 7.2 to 9.6]). Unadjusted incidence was significantly higher in women from most deprived (Scottish Index of Multiple Deprivation 1) than least deprived (Scottish Index of Multiple Deprivation 5) areas (10.1/100 000 [95% CI = 7.8 to 12.8] vs 3.9 [95% CI = 2.6 to 5.7]). Women from the most deprived areas showed a significant reduction in incidence following 3 doses of vaccine (13.1/100 000 [95% CI = 9.95 to 16.9] vs 2.29 [95% CI = 0.62 to 5.86]).

Conclusion

Our findings confirm that the bivalent vaccine prevents the development of invasive cervical cancer and that even 1 or 2 doses 1 month apart confer benefit if given at 12-13 years of age. At older ages, 3 doses are required for statistically significant vaccine effectiveness. Women from more deprived areas benefit more from vaccination than those from less deprived areas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus VaccinesPapillomavirus InfectionsHumansFemaleIncidenceAdolescentAdultYoung AdultChildScotlandMiddle AgedVaccinationAge FactorsRegistriesHuman Papillomavirus Viruses

Substanzen

Papillomavirus Vaccines

Autor:innen und Institutionen

  • Public Health Scotland, Glasgow, UK.
  • MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK.
  • Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK.
  • Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, Edinburgh, UK.
  • Edinburgh Clinical Research Facility, University of Edinburgh, Western General Hospital, Crewe Rd S, Edinburgh, UK.
  • Scottish Cervical Screening Programme, National Services Division Gyle Square, Edinburgh, UK.

ORCID-Profile: Tim J Palmer, Kate Cuschieri

Förderung

  • Scottish Government
  • Public Health Scotland

Zitieren

APA

Palmer, T. J., Kavanagh, K., Cuschieri, K., Cameron, R., Graham, C., Wilson, A., & Roy, K. (2024). Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation. JNCI: Journal of the National Cancer Institute, 116(6), 857-865. https://doi.org/10.1093/jnci/djad263

Vancouver

Palmer TJ, Kavanagh K, Cuschieri K, Cameron R, Graham C, Wilson A, et al. Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation. JNCI: Journal of the National Cancer Institute. 2024;116(6):857-865. doi:10.1093/jnci/djad263

BibTeX
@article{Palmer2024,
  author = {Palmer, Tim J and Kavanagh, Kimberley and Cuschieri, Kate and Cameron, Ross and Graham, Catriona and Wilson, Allan and Roy, Kirsty},
  title = {Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2024},
  volume = {116},
  number = {6},
  pages = {857--865},
  doi = {10.1093/jnci/djad263}
}
Kostenlos starten →